Differences in the Cerebral Amyloid Angiopathy Proteome in Alzheimer's Disease and Mild Cognitive Impairment

Differences in the Cerebral Amyloid Angiopathy Proteome in Alzheimer's Disease and Mild Cognitive Impairment

Cerebral amyloid angiopathy (CAA) is a disease caused by the deposition of amyloid-beta (Aβ) in cerebral blood vessels. It is common not only in the elderly and almost all patients with Alzheimer’s disease (AD) but can also occur independently of other AD-related pathologies. The presence and severity of CAA promote the progression of AD-related cl...

Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma

Research Report on Claudin 18.2 in Gastric Cancer and Gastroesophageal Junction Adenocarcinoma Background Introduction Gastric cancer and gastroesophageal junction (G/GEJ) adenocarcinoma are major global health burdens. It is estimated that in 2020 alone, there were approximately 1.7 million new cases of gastric and esophageal cancers worldwide, wi...

Regorafenib in Patients with Solid Tumors: Results from the TAPUR Study

The Use of Regorafenib in Patients with BRAF-Mutant Solid Tumors: A Summary of Results from the TAPUR Study Background Introduction The BRAF gene belongs to the cytoplasmic serine/threonine kinase family and regulates cell proliferation and survival by activating the mitogen-activated protein kinase signaling pathway (MAPK). BRAF mutations can lead...

Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care

In contemporary clinical oncology practice and drug development, the methods for evaluating tumor response are on the cusp of a revolution. Since the World Health Organization (WHO) proposed tumor response classification criteria for assessing the effectiveness of anti-cancer drugs in 1981, this field has undergone several improvements. Notably, th...

Plasma Proteome-Based Test for First-line Treatment Selection in Metastatic Non–Small Cell Lung Cancer

In the tumor microenvironment (Tumor Microenvironment, TME), Immune Checkpoint Inhibitors (ICIs) targeting PD-1 or PD-L1 enhance the body’s natural ability to eliminate cancer cells by disrupting the inhibitory receptor-ligand interaction. However, even so, critical trials indicate that the response rate for monotherapy is <50%, with a median Progr...

Prognostic Value of Serial Postoperative Circulating Tumor DNA Assessment During Long-Term Follow-Up in Patients with Breast Cancer

Prognostic Value of Serial Postoperative Circulating Tumor DNA Assessment During Long-Term Follow-Up in Patients with Breast Cancer

Scientific Research Report Background Introduction Breast cancer is the most commonly diagnosed cancer worldwide among both men and women, and it is the leading cause of cancer-related deaths in women. The standard treatment for early-stage breast cancer usually involves surgery and (neo)adjuvant chemotherapy and/or endocrine therapy, aiming to eli...